Physician profile
Toni M Murphy
NPI 1003862897
$39,111.58
in general payments reported to CMS, 2019-2025
45 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,790 · 2021: $11K · 2022: $1,132 · 2023: $1,349 · 2024: $1,115 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,610.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22,061.55 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $8,167.03 | 2019-2021 | |
| Lilly USA, LLC | $1,317.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,019.37 | 2019-2025 | Jardiance |
| Amgen INC. | $604.27 | 2019-2025 | Tepezza, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $585.55 | 2019-2023 | Xarelto |
| Abbvie INC. | $571.27 | 2019-2025 | |
| Medtronic, INC. | $498.08 | 2021-2025 | Minimed 780g, Guardian Connect |
| Horizon Therapeutics Plc | $396.21 | 2019-2023 | Tepezza |
| Mannkind Corporation | $295.02 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $290.08 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $289.20 | 2019-2025 | Unithroid |
| Dexcom, INC. | $281.79 | 2021-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $256.62 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $225.06 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.18 | 2019-2025 | |
| Abbott Laboratories | $166.85 | 2019-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $157.78 | 2024 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $149.80 | 2019-2021 | |
| Vistapharm, INC. | $127.31 | 2021 | |
| Xeris Pharmaceuticals, INC. | $123.32 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $120.48 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $119.09 | 2019-2023 | Crysvita |
| Tandem Diabetes Care, INC. | $108.81 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $91.53 | 2022-2024 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $90.69 | 2020-2025 | Tirosint, Licart, Flector |
| Novo Nordisk INC | $84.91 | 2019 | |
| Cequr Corporation | $80.09 | 2023-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $71.97 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $71.19 | 2020-2025 | Strensiq |
| Amarin Pharma, INC. | $55.74 | 2019-2020 | |
| Shire North American Group INC | $54.07 | 2019 | |
| Sequel Med Tech, LLC | $48.09 | 2025 | Twiist |
| Valeritas, INC. | $36.69 | 2019 | |
| Chiesi USA, INC. | $36.60 | 2024 | Mycapssa |
| Soleno Therapeutics, INC. | $32.46 | 2025 | Vykat Xr |
| Clarus Therapeutics INC. | $32.27 | 2021 | |
| Endo Pharmaceuticals INC. | $31.53 | 2019 | |
| Neurocrine Biosciences, INC. | $31.12 | 2025 | |
| Senseonics, Incorporated | $29.00 | 2019 | |
| Eusa Pharma (US) LLC | $24.64 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $24.21 | 2025 | |
| Astellas Pharma US INC | $23.64 | 2024 | Veozah |
| Radius Health, INC. | $20.97 | 2020 | |
| Antares Pharma, INC. | $19.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.